The stock has a 36-month beta value of 1.36. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NRSN is 15.47M, and at present, short sellers hold a 2.10% of that float. On December 11, 2024, the average trading volume of NRSN was 192.60K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NRSN) stock’s latest price update
NeuroSense Therapeutics Ltd (NASDAQ: NRSN)’s stock price has dropped by -7.84 in relation to previous closing price of 1.02. Nevertheless, the company has seen a loss of -12.15% in its stock price over the last five trading days. prnewswire.com reported 2024-12-11 that The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass., Dec. 11, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd.
NRSN’s Market Performance
NeuroSense Therapeutics Ltd (NRSN) has seen a -12.15% fall in stock performance for the week, with a -28.79% decline in the past month and a -27.13% plunge in the past quarter. The volatility ratio for the week is 9.99%, and the volatility levels for the past 30 days are at 10.55% for NRSN. The simple moving average for the past 20 days is -10.61% for NRSN’s stock, with a -21.05% simple moving average for the past 200 days.
NRSN Trading at -18.04% from the 50-Day Moving Average
After a stumble in the market that brought NRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.66% of loss for the given period.
Volatility was left at 10.55%, however, over the last 30 days, the volatility rate increased by 9.99%, as shares sank -29.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.95% lower at present.
During the last 5 trading sessions, NRSN fell by -12.15%, which changed the moving average for the period of 200-days by -47.78% in comparison to the 20-day moving average, which settled at $1.0516. In addition, NeuroSense Therapeutics Ltd saw 19.75% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NRSN
The total capital return value is set at 7.32. Equity return is now at value -602.40, with -173.59 for asset returns.
Currently, EBITDA for the company is -10.63 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.46.
Conclusion
To sum up, NeuroSense Therapeutics Ltd (NRSN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
